Wei Teng1,2,3, Wen-Juei Jeng1,2,3, Wei-Ting Chen1,3, Chen-Chun Lin1,3, Chun-Yen Lin1,3, Shi-Ming Lin1,3, I-Shyan Sheen1,3. 1. Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan. 2. Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan. 3. College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Abstract
BACKGROUND: A soluble form of cytotoxic-T-lymphocyte-antigen-4 (sCTLA-4) is a prognostic biomarker for several cancers but remains unclear in HCC patients. The aim of study is to evaluate the predictive role of serum sCTLA-4 levels for tumor recurrence of chronic hepatis C (CHC)-HCC patients receiving radiofrequency ablation (RFA). MATERIAL AND METHOD: A prospective study recruiting 88 CHC-HCC patients was done between 2013 and 2019. Cox regression analysis was used to determine the predictors of early recurrence. All tests were two-tailed, and the level of statistical significance was set as p < 0.05. RESULTS: During a median follow-up of 44.4 months, 53 of the 88 (60.2%) CHC-HCC patients encountered early recurrence within 2 years. The predictability of sCTLA-4 for local recurrence (LR) and intrahepatic metastasis (IHM) by 2-years using AUROC curve analysis were 0.740 and 0.715, respectively. Patients with high sCTLA-4 levels (>9 ng/ml) encountered shorter recurrence-free survival (RFS) for LR (log-rank p = 0.017) but paradoxically longer RFS for IHM (log-rank p = 0.007) compared to those with low levels (≤9 ng/ml). By multivariate Cox regression analysis, sCTLA-4 levels and antiviral therapy were independent prognostic factor of early recurrence both in LR and IHM. A combination of baseline sCTLA-4 and AFP level could improve the predictability of early LR and IHM with specificity of 80.0% and 79.7% and positive predictive value of 63.3% and 67.3%, respectively. CONCLUSIONS: sCTLA-4 level is a good predictor for early HCC recurrence with higher levels indicating susceptibility to early LR, but protecting from early IHM.
BACKGROUND: A soluble form of cytotoxic-T-lymphocyte-antigen-4 (sCTLA-4) is a prognostic biomarker for several cancers but remains unclear in HCC patients. The aim of study is to evaluate the predictive role of serum sCTLA-4 levels for tumor recurrence of chronic hepatis C (CHC)-HCC patients receiving radiofrequency ablation (RFA). MATERIAL AND METHOD: A prospective study recruiting 88 CHC-HCC patients was done between 2013 and 2019. Cox regression analysis was used to determine the predictors of early recurrence. All tests were two-tailed, and the level of statistical significance was set as p < 0.05. RESULTS: During a median follow-up of 44.4 months, 53 of the 88 (60.2%) CHC-HCC patients encountered early recurrence within 2 years. The predictability of sCTLA-4 for local recurrence (LR) and intrahepatic metastasis (IHM) by 2-years using AUROC curve analysis were 0.740 and 0.715, respectively. Patients with high sCTLA-4 levels (>9 ng/ml) encountered shorter recurrence-free survival (RFS) for LR (log-rank p = 0.017) but paradoxically longer RFS for IHM (log-rank p = 0.007) compared to those with low levels (≤9 ng/ml). By multivariate Cox regression analysis, sCTLA-4 levels and antiviral therapy were independent prognostic factor of early recurrence both in LR and IHM. A combination of baseline sCTLA-4 and AFP level could improve the predictability of early LR and IHM with specificity of 80.0% and 79.7% and positive predictive value of 63.3% and 67.3%, respectively. CONCLUSIONS: sCTLA-4 level is a good predictor for early HCC recurrence with higher levels indicating susceptibility to early LR, but protecting from early IHM.
Authors: N Nagasue; M Uchida; Y Makino; Y Takemoto; A Yamanoi; T Hayashi; Y C Chang; H Kohno; T Nakamura; H Yukaya Journal: Gastroenterology Date: 1993-08 Impact factor: 22.682
Authors: Johan Verhagen; Leona Gabrysová; Sophie Minaee; Catherine A Sabatos; Graham Anderson; Arlene H Sharpe; David C Wraith Journal: Proc Natl Acad Sci U S A Date: 2009-02-13 Impact factor: 11.205
Authors: Hans Jakob Hartling; Carsten Birch; Julie C Gaardbo; Malene Hove; Marius Trøseid; Mette Rye Clausen; Jan Gerstoft; Henrik Ullum; Susanne Dam Nielsen Journal: APMIS Date: 2015-08-17 Impact factor: 3.428
Authors: Frank J Ward; Lekh N Dahal; Subadra K Wijesekera; Sultan K Abdul-Jawad; Taniya Kaewarpai; Heping Xu; Mark A Vickers; Robert N Barker Journal: Eur J Immunol Date: 2013-03-06 Impact factor: 5.532